AnaptysBio, Inc.

133 articles about AnaptysBio, Inc.

• AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors

  9/18/2023

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors.

• AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit

  9/12/2023

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer, will present at the Stifel 2023 Immunology and Inflammation Virtual Summit later this month.

• AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update

  8/7/2023

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.

• AnaptysBio Announces Participation in Upcoming June 2023 Investor Conferences

  5/30/2023

  AnaptysBio, Inc. announced that Daniel Faga, interim president and chief executive officer of AnaptysBio, and other members of its senior management team are scheduled to participate in both of the upcoming investor conferences below:

• AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update

  5/11/2023

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the first quarter ended March 31, 2023 and provided pipeline updates.

• AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)

  5/2/2023

  AnaptysBio, Inc. (Nasdaq: ANAB) today announced the publication of data from the open-label, single-arm Phase 2 GALLOP study evaluating the efficacy, tolerability and safety of imsidolimab, its investigational anti-interleukin-36 receptor (IL-36R) IgG4 antibody for the treatment of generalized pustular psoriasis (GPP), in the British Journal of Dermatology.

• AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors

  4/6/2023

  AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced the appointment of Rita Jain, M.D., to the company’s Board of Directors, effective immediately.

• AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

  3/1/2023

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the fourth quarter and year ended December 31, 2022 and provided business updates.

• AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference

  2/27/2023

  AnaptysBio, Inc. announced that Dan Faga, interim president and chief executive officer, will present at the Cowen and Company 43rd Annual Health Care Conference on Monday, March 6, 2023, at 2:50 p.m. ET / 11:50 a.m. PT.

• AnaptysBio Announces Stock Repurchase Plan

  1/13/2023

  AnaptysBio, Inc. today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share.

• AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies

  1/5/2023

  AnaptysBio, Inc. announced a portfolio update including initiating development of its wholly owned best-in-class immune cell modulating antibodies in autoimmune and inflammatory diseases with large and significantly underserved patient populations.

• AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

  12/2/2022

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s RUBY/ENGOT-EN6/GOG3031/NSGO Phase 3 trial of JEMPERLI.

• AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference

  11/21/2022

  AnaptysBio, Inc. (Nasdaq: ANAB) today announced that Dan Faga, interim chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday November 29th, 2022, at 8:10 a.m. ET / 5:10 a.m. PT.

• AnaptysBio to Participate in Upcoming November 2022 Investor Conferences

  11/9/2022

  AnaptysBio, Inc. announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Monday November 14th, 2022, at 1:00 p.m. ET / 10:00 a.m.

• AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update

  11/8/2022

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the third quarter ended September 30, 2022 and provided pipeline updates.

• AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials

  10/5/2022

  AnaptysBio, Inc. today announced that GSK’s study PERLA met its primary endpoint of objective response rate (ORR) of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as assessed by blinded independent central review per RECIST v1.1.

• AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million

  9/12/2022

  AnaptysBio, Inc., a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced that the company has sold its royalty interest on future global net sales of Zejula to a wholly-owned subsidiary of DRI Healthcare Trust for up to $45 million.

• 

  Clinical Catch-Up: Vertex, BI, MannKind and More Share Updates

  9/6/2022

  ​​​​​​​It's been a busy week for research on rare diseases, with several clinical trials from AnaptysBio, Regenxbio, Sangamo and more posting results from ongoing activities.
• 

  AnaptysBio Pins Hopes on Pustular Psoriasis after Failed HS Trial

  9/1/2022

  Shares of AnaptysBio are down more than 16% after imsidolimab failed to meet the endpoint in a Phase II trial assessing its efficacy in hidradenitis suppurativa.

• AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

  8/31/2022

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced top-line data from its HARP Phase 2 trial for the treatment of moderate-to-severe hidradenitis suppurativa (HS).